Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

A Novel, High Sensitivity, Quantitative Hepatitis C Virus Assay

William Hauser1, Michael Mira1, Guiqing Wang, MD PhD1, Dieter Schapfel, MD1
1Enzo Life Sciences, Farmingdale, NY USA


Featured Product: AMPIPROBE® HCV assay kit

> Download the complete application note

INTRODUCTION

More than 170 million individuals are chronically infected with Hepatitis C Virus (HCV), and it is a major cause of hepatocellular carcinoma, liver cirrhosis, and liver-related mortality. Successful HCV treatment results in sustained virologic response (SVR), defined as undetectable levels of HCV RNA in the blood 12 or more weeks after completing treatment. A sensitive method to quantify HCV RNA is paramount to the management of patients undergoing antiviral therapy.

A quantitative HCV viral load assay using novel probe technology was validated for use in the quantitative detection of HCV RNA. The AMPIPROBE® HCV Assay is a real-time reverse transcription quantitative polymerase chain reaction assay that incorporates probe detection technology in primer design. It is intended for the quantitative detection of HCV RNA, genotypes 1 through 6, in plasma or serum.

The limit of detection (LOD) of the assay was determined using spiked plasma or serum specimens with Acrometrix® reference materials calibrated by using the World Health Organization HCV RNA standard per guidelines described in CLSI EP17-A. The LOD of HCV RNA in EDTA plasma was determined to be as low as 0.90 log IU/mL (7.9 IU/mL) and in serum as low as 0.74 log IU/mL (5.5 IU/mL), both with a positive rate greater than 95%. For both plasma and serum, the lower limit of quantification was 1.0 log IU/mL (10 IU/mL) via 95% hit rate analysis. A reference panel was utilized to confirm that the AMPIPROBE® HCV Assay was able to detect genotypes 1a, 1b, 2a, 3a, 4acd, 5a, and 6 at 15 IU/mL or greater at a 95% hit rate. The linear range was evaluated in accordance with the methods recommended in the CLSI guideline EP06-A. The linear range was determined to be from 0.7 to 7.4 log IU/mL (5 to 25,000,000 IU/mL).

The LOD and LOQ determined for the AMPIPROBE® HCV Assay are lower than that of comparable HCV viral load assays, making it a more sensitive assay suitable for monitoring viral load during antiviral therapy.

Read More about Genomics

TechNotes

Our bi-weekly TechNotes are an easy way for you to keep in touch with how Enzo Life Sciences is living up to our motto: Scientists Enabling Scientists™. Each TechNote connects recently published research with one or more of the many solutions Enzo provides for scientists across the life sciences, drug development, and clinical research communities.

Molecular Biology TechNotes

Genomics Product Range

Clear Results With Innovative Nucleic Acid Labeling

Genomics

 

Recommend this page

 
Keep in touch

©2017 Enzo Life Sciences, Inc.,